BioSpace News Archive

The ePharmacy market is growing at a rapid pace on the back of a growing number of technology-savvy consumers, improving digitization in healthcare services, and increasing penetration of internet connectivity at the global platform.

The implant disappears after fixation is completed, without leaving any foreign material on the tissue surface. Polyglycolic acid, polylactic acid, and polydioxanone are the predominantly used materials in the manufacture of bioabsorbable implants, as these have the ability to dissolve in the biological system.

Dexcom, Inc., a global leader in real-time continuous glucose monitoring, is happy to share that people with type 1 diabetes who are 25 years of age or under may now be eligible for provincial coverage of the Dexcom G6 CGM System through Manitoba Health and Seniors Care.

Amicus Therapeutics, Inc. announced its intent to launch a next-generation genetic medicine company, Caritas Therapeutics, Inc., through a definitive business combination agreement pursuant to which the Amicus gene therapy business will be acquired by ARYA Sciences Acquisition Corp IV, a special purpose acquisition company or SPAC, sponsored by Perceptive Advisors.

NovaBay® Pharmaceuticals, Inc. announces that management will discuss its acquisition of DERMAdoctor on an investment community conference call and webcast with accompanying slide presentation, Wednesday, September 29, 2021 beginning at 4:30 p.m. Eastern time.

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today reported additional positive pulmonary function data from the first six patients in the ongoing IGNITE DMD Phase I/II clinical trial of SGT-001.

Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), and a company it founded, Caelum Biosciences, Inc. (“Caelum”), today announced that AstraZeneca’s Alexion notified Caelum that it has exercised its option to acquire Caelum.

Jiangsu Recbio Technology Co., Ltd. (referred to as “Recbio”) and Shenzhen Rhegen Biotechnology Co., Ltd. (referred to as “Rhegen Bio”) recently signed a joint venture agreement to establish a joint venture company “Wuhan Rhecogen Biotechnology Co., Ltd.”

Orthofix Medical Inc . (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today provided a business update.

Helsinn Group and BridgeBio Pharma, Inc. (Nasdaq: BBIO), through its affiliate QED Therapeutics, Inc., today announced that Health Canada has approved TRUSELTIQ™ (infigratinib), a small molecule kinase inhibitor that targets fibroblast growth factor receptor (FGFR.